KPTI

Karyopharm Therapeutics Inc

KPTI.US karyopharm.com
1.62
-0.07 (-4.14%)
USD · NASDAQ
52-week range
1.60
10.99
Trading at 0% of the 52-week range
Market Cap
36.74M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
-14.56
Div. Yield
N/A
% Institutions
97.98%
% Insiders
4.67%

1 Year

-73.9%

3 Year

-91.1%

10 Year

-98.8%
Description

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Company Information

Company Name
Karyopharm Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US48576U2050
CIK: 0001503802
CUSIP: 48576U106
Currency: USD
Full Time Employees: 228
Phone: 617 658 0600
Fiscal Year End: December
IPO Date: Nov 06, 2013
Description:

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Address:

85 Wells Avenue, Newton, MA, United States, 02459-3298

People

Directors & Officers

Name Title Year Born
Mr. Richard A. Paulson M.B.A. President, CEO & Director 1967
Mr. Stuart Poulton Executive VP & Chief Development Officer 1973
Dr. Reshma Rangwala M.D., Ph.D. Executive VP, Chief Medical Officer & Head of Research 1978
Dr. Sharon Shacham M.B.A., Ph.D. Co-Founder & Chairman of Scientific Advisory Board 1970
Ms. Lori A. Macomber CPA EVP, CFO & Treasurer 1971
Ms. Kristin Abate VP, Chief Accounting Officer & Assistant Treasurer NA
Mr. Brendan Twohig Strong Senior Vice President of Investor Relations NA
Mr. Michael J. Mano J.D. Executive VP, Chief Legal Officer & Secretary 1977
Mr. James Accumanno J.D. Chief Compliance Officer NA
Ms. Lisa DiPaolo Executive VP & Chief Human Resource Officer NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 21, 2026 Reshma Rangwala N/A Sale 449.00 $8.94 $4.01K
Jan 28, 2026 Kristin Abate N/A Sale 50.00 $7.03 $351.50
Jan 21, 2026 Kristin Abate N/A Sale 265.00 $5.96 $1.58K
Oct 01, 2025 Kristin Abate N/A Sale 362.00 $6.30 $2.28K
Sep 15, 2025 Kristin Abate N/A Sale 23.00 $6.43 $147.89
Sep 15, 2025 Michael Mano N/A Sale 234.00 $6.43 $1.50K
Sep 15, 2025 Reshma Rangwala N/A Sale 408.00 $6.43 $2.62K
Sep 15, 2025 Sohanya Roshan Cheng N/A Sale 325.00 $6.43 $2.09K
Sep 15, 2025 Stuart Poulton N/A Sale 401.00 $6.43 $2.58K
Sep 03, 2025 Kristin Abate N/A Sale 12.00 $6.78 $81.36
Jul 29, 2025 Stuart Poulton N/A Sale 191.00 $4.37 $834.67
Jul 22, 2025 Kristin Abate N/A Sale 238.00 $4.00 $952.00

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
COMMODORE CAPITAL LP 1.95M Mar 31, 2026 8.60% $0.63 0.00%
RA Capital Management, LLC 1.92M Mar 31, 2026 8.45% $0.11 0.00%
T. Rowe Price Investment Management,Inc. 1.54M Mar 31, 2026 6.80% $0.01 -25.77%
Adage Capital Partners Gp LLC 1.52M Jun 30, 2026 6.71% $0.02 -15.78%
The Goldman Sachs Group Inc 947.58K Mar 31, 2026 4.18% $0.00 0.00%
Catalio Capital Management, LP 940.86K Jun 30, 2026 4.15% $1.73 4.81%
Avidity Partners Management LP 924.49K Jun 30, 2026 4.08% $1.45 -0.32%
Vanguard Capital Management, LLC 739.75K Mar 31, 2026 3.26% $0.00 0.00%
Ikarian Capital, LLC 733.44K Mar 31, 2026 3.23% $0.33 34.69%
Affinity Asset Advisors, LLC 500.00K Mar 31, 2026 2.20% $0.14 -43.79%
Soleus Capital Management, L.P. 440.00K Jun 30, 2026 1.94% $0.15 0.00%
Millennium Management LLC 305.68K Jun 30, 2026 1.35% $0.00 -27.32%
Boxer Capital Management, LLC 302.54K Mar 31, 2026 1.33% $0.22 19.80%
Davidson Kempner Capital Management LP 300.00K Mar 31, 2026 1.32% $0.02 -3.23%
Eversept Partners, LP 276.17K Jun 30, 2026 1.22% $0.14 0.00%
Jump Financial LLC 262.15K Mar 31, 2026 1.16% $0.02 387.12%
Trexquant Investment LP 257.90K Mar 31, 2026 1.14% $0.01 517.98%
Acadian Asset Management LLC 248.96K Mar 31, 2026 1.10% $0.00 0.00%
BlackRock Inc 244.90K Mar 31, 2026 1.08% $0.00 -1.07%
BOOTHBAY FUND MANAGEMENT, LLC 213.81K Mar 31, 2026 0.94% $0.02 47.83%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 677.73K 2.99% ▲ 0.00% Jul 31, 2026
2 iShares Russell 2000 ETF 482.93K 2.13% ▼ 0.57% Aug 31, 2026
3 T. Rowe Price U.S. SC Value Eq Tr-D 312.41K 1.38% ▼ 48.87% Jun 30, 2026
4 Vanguard Institutional Extnd Mkt Idx Tr 263.08K 1.16% ▲ 0.00% Jul 31, 2026
5 Fidelity Small Cap Index 214.60K 0.95% ▲ 0.00% Jun 30, 2026
6 Fidelity Enhanced Small Cap Core ETF 174.36K 0.77% ▲ 0.29% Aug 31, 2026
7 iShares Russell 2000 Value ETF 151.90K 0.67% ▼ 0.23% Aug 31, 2026
8 Russell 2000 Index Non-Lendable Fund 128.78K 0.57% ▲ 0.00% Jun 30, 2026
9 Russell 2000 Equity Index Fund B 128.78K 0.57% ▲ 0.00% Jun 30, 2026
10 Vanguard Russell 2000 ETF 111.50K 0.49% ▼ 3.17% Jul 31, 2026

Financial Highlights

Market Cap: $36.74M
EBITDA: $-82.20M
PEG Ratio: $-0.15
Book Value: $-14.56
Earnings/Share: $-13.74
Profit Margin: -153.28%
Operating Margin: -67.38%
ROA (TTM): -47.61%
ROE (TTM): -891.05%
Revenue (TTM): $146.62M
Revenue/Share (TTM): $7.55
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -11.90%

Valuation Metrics

Enterprise Value: $229.42M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 22.68M
Shares Float: 15.77M
% Insiders: 4.67%
% Institutions: 97.98%
Short % Float: 42.72%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$146.07M
Cost of Goods Sold
adjust
$-5.95M
Gross Profit
subtotal
$140.12M
SG&A
adjust
$-105.21M
R&D
adjust
$-125.62M
Operating Income
subtotal
$-90.71M
Other / Non-Operating Items
adjust
$-105.33M
Net Income
subtotal
$-196.04M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about KPTI.US!